Posted by Michael Wonder on 16 Jan 2019
Amneal announces approval of rivastigmine transdermal system
14 January 2019 - Amneal Pharmaceuticals today announced that it has received FDA approval for a generic version of Exelon Patch (rivastigmine transdermal system), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours.
The Company is planning to commercialise its rivastigmine transdermal system shortly.
